Compare SCSC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCSC | GYRE |
|---|---|---|
| Founded | 1992 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 606.4M |
| IPO Year | 1997 | 2004 |
| Metric | SCSC | GYRE |
|---|---|---|
| Price | $58.59 | $6.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $43.00 | $17.00 |
| AVG Volume (30 Days) | ★ 301.5K | 57.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.33 | N/A |
| EPS | ★ 3.64 | N/A |
| Revenue | ★ $3,846,260,000.00 | $275,000.00 |
| Revenue This Year | $2.60 | $19.88 |
| Revenue Next Year | $4.01 | N/A |
| P/E Ratio | $15.99 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $33.76 | $5.44 |
| 52 Week High | $66.78 | $9.42 |
| Indicator | SCSC | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 53.40 |
| Support Level | $49.77 | $6.44 |
| Resistance Level | $59.46 | $8.20 |
| Average True Range (ATR) | 1.84 | 0.25 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 76.40 | 49.74 |
ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.